Lexicon Pharma shares halted pending news
Mar. 22, 2019 12:52 PM ETLexicon Pharmaceuticals, Inc. (LXRX), SNYSNY, LXRXBy: Douglas W. House, SA News Editor11 Comments
- Nasdaq has suspended trading in Lexicon Pharmaceuticals (LXRX -5.3%) pending the release of news, a near-certainty that it pertains to the expected FDA nod for Sanofi's (SNY -2.6%) oral Zynquista (sotagliflozin) for type 1 diabetes. Today is the agency's action date.
- Sanofi in-licensed the dual SGLT-1 & 2 inhibitor from Lexicon in November 2015.
- Approval should trigger a milestone payment to LXRX.